Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study

ESSENTIALS: Idarucizumab, a monoclonal antibody fragment, binds dabigatran with high affinity and specificity. In this phase 1 trial, healthy Japanese males received idarucizumab alone or with dabigatran. Idarucizumab achieved immediate, complete and sustained reversal of dabigatran anticoagulation....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Res Pract Thromb Haemost
Glavni autori: Yasaka, Masahiro, Ikushima, Ippei, Harada, Akiko, Imazu, Susumu, Taniguchi, Atsushi, Norris, Stephen, Gansser, Dietmar, Stangier, Joachim, Schmohl, Michael, Reilly, Paul A.
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2017
Teme:
Original Articles: Thrombosis
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6058259/
https://ncbi.nlm.nih.gov/pubmed/30046691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12029
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items